SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to a significant surge following FDA Breakthrough Therapy Designation for its drug targeting a rare disease, Sanfilippo syndrome type B. The community is discussing the potential for continued gains, a possible short squeeze, and comparing it to other high-flying stocks. Some traders express caution, pointing to the company's financials and the potential for a pullback, while others are excited about the long-term potential.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Siyata Mobile Inc

Siyata Mobile ($SYTA) is trending as it finalizes its merger with Core Gaming, set to trade under the ticker $CHAI next week, which has spurred discussion around the reverse stock split and its potential impact. The community is actively debating the valuation of the combined entity, the lock-up period for major shareholders, and the possibility of a squeeze. Some traders are optimistic about the AI-driven mobile gaming and app platform's future, while others express concerns about dilution and historical performance.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after news of a multi-year AI compute deal with OpenAI, including potential stock warrants, fueled bullish sentiment. Community members are discussing the potential impact on market share and revenue, with some analysts raising price targets significantly. The conversation highlights a possible shift in the AI chip landscape and increased competition for Nvidia.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to its recent NASDAQ listing and a partnership with a major Korean payment processor, sparking community discussion about its potential in quantum-secure stablecoin settlements.  Some investors are drawing comparisons to other quantum computing stocks and suggesting BTQ is undervalued, while others express concern about revenue and potential dilution. The community is closely watching for increased institutional and retail investor attention.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp ($LAES) is trending due to significant premarket hype and discussions around potential breakouts, with community members eyeing targets as high as $10. Conversations highlight the company's upcoming chip launch and its positioning in the quantum computing sector alongside names like $NVDA and $QBTS. Some caution about potential dilution, while others express strong bullish sentiment, anticipating a short squeeze and parabolic continuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp ($CRML) is trending amid speculation and conflicting reports regarding potential US government investment in its Greenland rare earth project, with community members debating the validity of news sources and the implications of a possible deal. The stock experienced significant volatility, leading to discussions about market manipulation and the strategic importance of rare earth minerals. Community members are also discussing a potential short squeeze.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Fueled by community enthusiasm, Rigetti Computing is trending as retail investors discuss the potential for a short squeeze and the broader implications of quantum computing's advancements. Some traders are closely watching the stock's momentum, while others express concern about its high valuation relative to revenue. Discussions also touch on Rigetti's place in the quantum computing race against competitors like IBM and Google.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to speculation of a potential partnership with Tesla, sparked by a teaser video featuring Archer's eVTOL aircraft alongside Tesla's Optimus robot. The community is actively discussing potential price targets and the likelihood of a formal announcement from either company. Broader interest in the eVTOL sector and Archer's existing partnerships are also contributing to the buzz.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending amid discussions around a potential crypto launch and expansion into new financial services, sparking bullish sentiment among investors. Community members are weighing in on the company's growth prospects and comparing it to competitors, while some anticipate a short squeeze. Technical analysis suggests key support and resistance levels are being closely monitored as traders assess the stock's momentum.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the nostalgia of internet rage comics and memes. Community members express excitement, referencing potential 'moonshot' gains and emphasizing the strength of the growing community. The coin is seen as a revival of early internet culture, embodying the raw, chaotic energy of the original memes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Are Medical Stocks Lagging  Amgen (AMGN) This Year?

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Shares of Aldeyra Therapeutics, Inc. (ALDX) slumped nearly 71% on Thursday morning after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food-0">said</a> that the U.S. Food and Drug Administration (FDA) said the company’s investigational drug candidate reproxalap failed to demonstrate efficacy in treating ocular symptoms associated with dry eyes.The FDA told the company to resubmit its application for reproxalap and called upon the company to conduct “at least one additional adequate and well-controlled study” to demonstrate the drug’s positive effect on treating ocular symptoms of dry eye.The FDA, however, identified no manufacturing or safety issues with reproxalap, the company said.Aldeyra first submitted an application to the FDA for reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024.Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.On Stocktwits, retail investor sentiment about Aldeyra jumped further into the ‘extremely bullish’ territory (96/100), while message volume remained ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_10_14_30_AM_png_cb23178c6c.webp" alt="ALDX's Sentiment Meter and Message Volume as of 10:10 a.m. ET on April 3, 2025 | Source: Stocktwits" width="649" height="156"><figcaption>ALDX's Sentiment Meter and Message Volume as of 10:10 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the dip is a good opportunity to buy, highlighting the company’s cash balance. Aldeyra reported cash, cash equivalents, and marketable securities of $101 million as of the end of 2024.<stembedurl>https://stocktwits.com/Pizza_guy/message/610251728</stembedurl>Another user, however, speculated the company may be facing bankruptcy.<stembedurl>https://stocktwits.com/jacobs0009/message/610251451</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra shares</a> are down by over 70% this year and by over 60% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poni-ai-gets-robotaxi-testing-permit-in-luxembourg/chf7R7QRbe0">Pony AI Stock Draws Investor Attention On Robotaxi Testing Permit In Luxembourg: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic

Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.

Equity

Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.


Aldeyra Therapeutics to Participate in Oppenheimers 35th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical...

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALDX News

ALDX Aldeyra Therapeutics Inc